Close



Apr 18, 2024 07:30AM
Apr 18, 2024 07:30AM
Apr 16, 2024 07:31AM
Apr 16, 2024 07:30AM
Mar 19, 2024 11:53AM
Mar 19, 2024 11:53AM
Mar 15, 2024 07:30AM Cybin (CYBN) Initiates Phase 2 Proof-of-Concept Study of CYB004
Mar 15, 2024 07:30AM
Mar 14, 2024 07:30AM
Mar 14, 2024 07:30AM
Mar 13, 2024 07:02AM
Mar 13, 2024 07:00AM
Mar 13, 2024 06:00AM
Mar 13, 2024 06:00AM Cybin Receives FDA Breakthrough Therapy Designation for its Novel Psychedelic Molecule CYB003 and Announces Positive Four-Month Durability Data in Major Depressive Disorder
Feb 14, 2024 07:45AM
Feb 7, 2024 07:37AM
Feb 7, 2024 07:30AM
Jan 23, 2024 07:30AM
Jan 23, 2024 07:30AM
Jan 8, 2024 07:34AM
Jan 8, 2024 07:34AM Cybin Announces Positive Topline Data from Phase 1 Studies of Proprietary Deuterated DMT Molecules CYB004 and SPL028
Jan 4, 2024 07:33AM
Jan 4, 2024 07:32AM
Dec 6, 2023 07:31AM
Dec 6, 2023 07:30AM
Dec 5, 2023 07:30AM
Nov 30, 2023 07:34AM
Nov 30, 2023 07:30AM Cybin Reports Positive Topline Data from Phase 2 Study of CYB003 in Major Depressive Disorder with 79% of Patients in Remission after Two 12mg Doses
Nov 20, 2023 07:30AM
Nov 15, 2023 07:30AM
Nov 14, 2023 07:16PM
Nov 14, 2023 01:00PM
Nov 10, 2023 08:04AM
Nov 10, 2023 08:03AM
Nov 1, 2023 07:32AM Cybin Inc (CYBN) Provides Corporate Update and Highlights Key Upcoming Milestones Across its Development Pipeline
Nov 1, 2023 07:30AM
Oct 31, 2023 09:00AM
Oct 31, 2023 07:45AM
Oct 31, 2023 07:45AM
Oct 26, 2023 07:30AM
Oct 25, 2023 07:30AM
Oct 23, 2023 07:33AM Cybin Completes Acquisition of Small Pharma Inc. to Create International Clinical-stage Leader in Novel Psychedelic Therapeutics
Oct 17, 2023 05:35PM
Oct 12, 2023 05:00PM
Oct 6, 2023 07:30AM
Oct 3, 2023 07:30AM
Sep 27, 2023 07:30AM
Sep 27, 2023 07:30AM
Sep 26, 2023 07:30AM Cybin Announces Agreement with Fluence to Support Scaling of EMBARK Training for CYB003 Phase 3 Trial
Sep 21, 2023 05:00PM

251,757 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All